8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 20, 2012

REPLIGEN CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	0-14656	04-2729386
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA		02453
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (781) 250-0111

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 21, 2012, Repligen Corporation (the “Company”) announced that Jonathan I. Lieber would be appointed Chief Financial Officer, Treasurer and principal financial officer of the Company, effective September 20, 2012 (the “Start Date”).

Jonathan I. Lieber, age 43, has over 18 years of healthcare financial leadership and investment banking experience. He will be responsible for leading the Company’s financial activities, including financial strategy and risk management. Prior to joining the Company, from 2009-2012, Mr. Lieber held the position of Chief Financial Officer and Treasurer at Xcellerex, Inc., a supplier of bioprocessing products and disposable biomanufacturing technologies which was acquired in May 2012 by GE Healthcare. He was previously with Altus Pharmaceuticals, Inc. for seven years, and held the position of Chief Financial Officer and Treasurer from 2006-2009. Mr. Lieber holds a B.S. in business administration from Boston University and an M.B.A. in finance from New York University Stern School of Business.

In connection with his employment, the Company entered into a letter agreement, dated September 20, 2012 (the “Letter Agreement”) which sets forth certain terms of Mr. Lieber’s employment. There are no other arrangements or understandings between Mr. Lieber and any other persons pursuant to which he was selected as the Company’s Chief Financial Officer, Treasurer and principal financial officer. Additionally, there are no transactions involving the Company and Mr. Lieber that the Company would be required to report pursuant to Item 404(a) of Regulation S-K.

Pursuant to the terms of the Letter Agreement, Mr. Lieber will receive an annual base salary of $300,000 and he will be eligible to receive an annual performance bonus under the Company’s Executive Incentive Compensation Plan. The Company will target such bonus at up to 35% of Mr. Lieber’s annual base salary; however, the actual bonus percentage is discretionary and will be subject to the Board of Directors’ assessment of Mr. Lieber’s performance as well as general business conditions at the Company.

The Letter Agreement further provides that the Board of Directors will grant Mr. Lieber an incentive stock option to purchase 110,000 shares of the Company’s common stock (the “Option Grant”) under the Company’s 2012 Stock Option and Incentive Plan (the “Plan”). Twenty percent (20%) of the Option Grant will vest and become exercisable on the first, second, third, fourth and fifth anniversaries of the date of grant. The Letter Agreement also provides that the Board of Directors will grant Mr. Lieber an inducement equity award outside of the Plan, in accordance with NASDAQ Listing Rule 5635(c)(4), for 15,000 shares of restricted stock which will vest in full on the first anniversary of the Start Date. Mr. Lieber will be eligible to participate in all customary employee benefit plans or programs of the Company generally available to the Company’s full-time employees and/or executive officers.

Additionally, the Letter Agreement provides that Mr. Lieber’s employment with the Company is at will and may be terminated by either party at any time with or without notice and for any or no reason or cause. In the event Mr. Lieber’s employment is terminated without cause, Mr. Lieber will be entitled to receive severance pay equal to six months of his base salary in effect as of the termination date (less required deductions and withholdings) to be paid in the form of salary continuation on the Company’s standard payroll dates following the termination date. Mr. Lieber will also receive a continuation of group health insurance coverage through COBRA for a period of six months with the cost of such benefits to be shared in the same relative proportion by the Company and Mr. Lieber as in effect on the date of termination.

The foregoing description of the Letter Agreement is qualified in its entirety by reference to the Letter Agreement, which is filed with this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference.

On September 20, 2012, the Board of Directors of the Company approved the replacement of William J. Kelly as the Company’s Chief Financial Officer, Treasurer and principal financial officer, effective upon the commencement of Mr. Lieber’s employment as further described above in this Current Report on Form 8-K. Mr. Kelly will remain with the Company and serve as the Company’s Chief Accounting Officer and principal accounting officer.

Item 8.01. Other Events.

On September 21, 2012, the Company issued a press announcing Mr. Lieber’s appointment as Chief Financial Officer of the Company. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

10.1	Letter Agreement, dated as of September 20, 2012, by and between Repligen Corporation and Jonathan I. Lieber.
99.1	Press Release by Repligen Corporation, dated September 21, 2012.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	REPLIGEN CORPORATION
Date: September 21, 2012	By:	/s/ Walter C. Herlihy
		Walter C. Herlihy
		President and Chief Executive Officer

EXHIBIT INDEX

Exhibit No.	Exhibit
10.1	Letter Agreement, dated as of September 20, 2012, by and between Repligen Corporation and Jonathan I. Lieber.
99.1	Press Release by Repligen Corporation, dated September 21, 2012.

EX-10.1

Exhibit 10.1

SEPTEMBER 20, 2012

Jonathan Lieber

4 High Rock Terrace

Chestnut Hill, Massachusetts 02467

Re: Employment Agreement

Dear Jon:

This letter agreement (the “Agreement”) sets forth the terms of your employment with Repligen Corporation (the “Company”). This Agreement supersedes any prior oral or written agreements or understandings related to the terms and conditions of your employment.

1. Position. Your position with the Company will be Chief Financial Officer and Treasurer and you will report directly to the Chief Executive Officer of the Company. This is a full-time position. While you render services to the Company, you will not engage in any other employment, consulting or other business activity (whether full-time or part-time) that would create a conflict of interest with the Company.

2. Start Date. Your employment will begin on September 20, 2012, unless another date is mutually agreed upon by you and the Company. For purposes of this Agreement, the actual first day of your employment shall be referred to as the “Start Date.”

3. Salary. The Company will pay you a salary at the rate of $300,000 per year (the “Base Salary”), payable in accordance with the Company’s standard payroll schedule and subject to applicable deductions and withholdings. Your salary will be subject to periodic review and adjustments at the Company’s discretion.

4. Annual Bonus. You will be eligible to receive an annual performance bonus under the Company’s Executive Incentive Compensation Plan (or such other applicable plan or program adopted by the Company) (the “Bonus Plan”). The Company will target the bonus at up to 35% of the Base Salary. The actual bonus percentage is discretionary and will be subject to the Company’s assessment of your performance, as well as business conditions at the Company. The bonus also will be subject to approval by and adjustment at the discretion of the Company’s board of directors and the terms of the Bonus Plan; provided that you shall be eligible for a prorated bonus for 2012 based upon the number of days in 2012 that you work for the Company. The annual performance bonus, if any, shall be paid between January 1^st and March 15^th of the calendar year following the applicable bonus year. The Company expects to review your job performance on an annual basis and will discuss with you the criteria which the Company will use to assess your performance for bonus purposes. The Company also may make adjustments in the targeted amount of your annual performance bonus.

5. Stock Options. The Company shall grant you an incentive stock option to purchase 110,000 shares of the Company’s Common Stock (the “Option Grant”) under the Company’s 2012 Stock Option and Incentive Plan (the “Plan”). The foregoing options shall be issued at an

Page 2

exercise price equal to the fair market value of the Common Stock as determined by the Company’s board of directors on the date of grant (the “Grant Date”). Twenty percent (20%) of the Option Grant shall vest and become exercisable on the first, second, third, fourth and fifth anniversaries of the Grant Date, respectively, and the Option Grant shall be further subject to the terms and conditions set forth in the Plan and the Company’s associated Incentive Stock Option Agreement.

6. Restricted Stock. The Company shall grant you a Restricted Stock Award (as defined in the Plan) under the Plan representing 15,000 shares of the Company’s Common Stock (the “Restricted Stock Award”). The Restricted Stock Award shall vest in full on the one-year anniversary of the Start Date and shall be further subject to the terms and conditions set forth in the Plan and the Company’s associated Restricted Stock Award Agreement (the Plan, the Incentive Stock Option Agreement and the Restricted Stock Award Agreement, collectively, the “Equity Documents”).

7. Benefits. You will be eligible to participate in the employee benefits and insurance programs generally made available to the Company’s full-time employees which currently include health, life, short and long-term disability and a 401(k) plan. Details of these benefits programs, including mandatory employee contributions, and, if applicable, waiting periods, will be made available to you when you start. You will also be eligible for up to 25 days of Paid Time Off per year (vacation and sick/personal time) which shall accrue on a prorated basis, in accordance with the Company’s vacation policy as in effect from time to time.

8. At-will Employment, Severance. Your employment is “at will,” meaning you or the Company may terminate it at any time for any or no reason at which time you will be entitled to Accrued Obligations, defined as (1) the portion of your Base Salary that has accrued prior to any termination of your employment with the Company and has not yet been paid, (2) an amount equal to the value of your accrued unused vacation days and (3) the amount of any expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed and to no other compensation, provided, however, in the event the Company terminates your employment without Cause (as defined below), in addition to the Accrued Obligations, the Company shall provide to you the following termination benefits (the “Termination Benefits”) for a period of 6 months:

(i) continuation of your base salary at the rate then in effect in accordance with the terms of the Company’s standard payroll schedule (solely for purposes of Section 409A of the Internal Revenue Code of 1986, as amended, each payment is considered a separate payment (“Salary Continuation Payments”)); and

(ii) continuation of group health plan benefits to the extent authorized by and consistent with 29 U.S.C. § 1161 et seq. (commonly known as “COBRA”), with the cost of the regular premium for such benefits shared in the same relative proportion by the Company and you as in effect on the date of termination.

Notwithstanding anything to the contrary in this Agreement, you shall not be entitled to any Termination Benefits unless you first (i) enter into, do not revoke, and comply with the terms of

Page 3

a separation agreement in a form acceptable to the Company which shall include mutual releases of you and the Company and related persons and entities (the “Release”); (ii) resign from any and all positions, including, without implication of limitation, as a director, trustee, and officer, that you then hold with the Company and any affiliate of the Company; and (iii) return all Company property and comply with any instructions related to deleting and purging duplicates of such Company property. The Salary Continuation Payments shall commence within 60 days after the date of termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Salary Continuation Payments shall begin to be paid in the second calendar year. All compensation and benefits payable to you, other than the Termination Benefits, shall terminate on the date of termination of your employment.

9. Representation Regarding Other Obligations. This offer is conditioned on your representation that your employment activities will not be limited by any confidentiality, noncompetition or other agreement and further, that your ability to devote full time and attention to your work at the Company will not be impacted by any such agreement, including without limitation your Confidentiality, Non-Competition and Non-solicitation agreement with Xcellerex dated May 9, 2012, a copy of which you have provided to the Company. If you have entered into any other agreement that may restrict your activities on behalf of the Company, please provide Walter C. Herlihy with a copy of such agreement as soon as possible. You also represent that you have not used and will not use or disclose any trade secret or other proprietary right of any previous employer or any other party.

10. Definitions. For purposes of this Agreement:

“Cause” means (i) conduct constituting a material act of misconduct in connection with the performance of your duties, including, without limitation, misappropriation of funds or property of the Company or any of its subsidiaries or affiliates other than the occasional, customary and de minimis use of Company property for personal purposes; (ii) the commission of any felony or a misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) non-performance or unsatisfactory performance of your duties hereunder (other than by reason of your physical or mental illness, incapacity or disability) as determined in good faith by the Company and which has continued for more than 30 days following written notice; (iv) a breach by you of any of the provisions contained in any other written agreement by and between you and the Company; (v) a material violation of any of the Company’s written employment policies as applied to other employees in the Company which has continued for more than 30 days following written notice; or (vi) failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation.

11. Taxes; Section 409A. All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or its board of directors related to tax liabilities arising from your

Page 4

compensation. Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of the Code, the Company determines that you are a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement on account of your separation from service would be considered deferred compensation subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after your separation from service, or (B) your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year. Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon your termination of employment, then such payments or benefits shall be payable only upon your “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-l(h). The Company and you intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.

12. Interpretation, Amendment and Enforcement. This Agreement and the Equity Documents, as modified herein, constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with, this Agreement, your employment with the Company or any other relationship between you and the Company (the “Disputes”) will be governed by Massachusetts law, excluding laws relating to conflicts or choice of law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the Commonwealth of Massachusetts in connection with any Dispute or any claim related to any Dispute.

Page 5

13. Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and assigns, including any corporation with which or into which the Company may be merged or which may succeed to its assets or business.

14. Other Terms. Your employment with the Company will be on an “at will” basis. In other words, you or the Company may terminate your employment for any reason and at any time, with or without cause. Although your job duties, title, compensation and benefits, as well as the Company’s benefit plans and personnel policies and procedures, may change from time to time, the “at will” nature of your employment may only be changed in an express written agreement signed by you and the Company.

In addition, this offer is subject to satisfactory background and reference checks. As with all employees, our offer to you is also contingent on your submission of satisfactory proof of your identity and your legal authorization to work in the United States. You also will be required to sign, as a condition of your employment, the Company’s standard form of non-disclosure agreement.

We are excited about the prospect of having you join the Company. We look forward to receiving a response from you within one week acknowledging, by signing below, that you have accepted this Agreement.

Very truly yours,
By:	/s/ Walter C. Herlihy
Name:	Walter C. Herlihy
Title:	President and Chief Executive Officer

I have read and accept this employment offer:

By:	/s/ Jonathan Lieber
Name:	Jonathan Lieber
Dated:	9/20/12

EX-99.1

Exhibit 99.1

	Repligen Corporation
	41 Seyon Street
	Building #1, Suite 100
	Waltham, Massachusetts 02453
	Telephone: (781) 250-0111
	Telefax: (781) 250-0115

Repligen Appoints Jonathan I. Lieber as CFO

- Former CFO of Xcellerex, Inc. Joins Repligen Executive Management Team -

WALTHAM, MA – September 21, 2012 – Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jonathan I. Lieber to the position of Chief Financial Officer and Treasurer, effective immediately. Mr. Lieber most recently held the position of CFO and Treasurer at Xcellerex, Inc., a supplier of bioprocessing products and disposable biomanufacturing technologies, which was acquired in May 2012 by GE Healthcare. He will be responsible for leading Repligen’s financial activities, including long-term financial strategy and risk management. Repligen’s current CFO William J. Kelly has been named Chief Accounting Officer, overseeing the Company’s accounting and management reporting functions, as well as its internal controls.

“We are pleased to welcome Jonathan Lieber to the CFO role,” said Walter C. Herlihy, Ph.D., President and Chief Executive Officer at Repligen. “Over the past nine months, Repligen has become a profitable, significantly larger and more complex multinational organization. As the Company enters its next phase of growth, Mr. Lieber brings a particularly relevant skill set to the management team. His combined life sciences and capital markets expertise will be major assets to the Company as we advance on our strategy to further expand Repligen’s bioprocessing business and deliver top-tier financial performance.”

During his three-year tenure with Xcellerex, Mr. Lieber led the company’s accounting, finance, legal and corporate communications activities. He restructured the finance department and implemented business processes to support substantial revenue growth. Prior to his role with Xcellerex, Mr. Lieber was with Altus Pharmaceuticals for seven years, most recently as Senior Vice President, CFO and Treasurer. At Altus, he had responsibility for accounting and finance, and for managing several administrative departments. Mr. Lieber led all capital raising activities at the company, resulting in net proceeds to Altus of $250 million, including its $110 million initial public offering. Prior to joining Altus, Mr. Lieber served as vice president of SG Cowen’s Healthcare Investment Banking Group, where he originated and executed on multiple corporate financings and merger & acquisition transactions. Mr. Lieber has been involved in healthcare financings totaling over $3 billion in common stock and over $500 million in initial public offerings. He received a B.S. in business administration and finance from Boston University and an M.B.A. in finance from New York University Stern School of Business.

In connection with Mr. Lieber’s appointment, Repligen granted Mr. Lieber an inducement equity

- more -

Repligen Appoints Jonathan I. Lieber as CFO,

September 21, 2012

Page 2 of 3

award outside of Repligen’s 2012 Stock Option and Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). This award, which was approved by Repligen’s compensation committee and is consistent with Repligen’s past practice for new executive hires, is for 15,000 shares of restricted stock which will vest in full on the first anniversary of Mr. Lieber’s start date with Repligen.

About Repligen Corporation

Repligen Corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a leading manufacturer of Protein A, a critical reagent used to manufacture monoclonal antibody-based therapeutics. We also supply several growth factor products used to increase cell culture productivity in biomanufacturing. In the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of OPUS™ (Open Platform User Specified) single-use chromatography columns used in the biologics purification process. In addition to our core bioprocessing business, we have a portfolio of clinical-stage partnering assets, including two central nervous system orphan drug candidates and a pancreatic imaging agent in Phase 3 development. Repligen’s corporate headquarters are located in Waltham, MA, USA; we have an additional manufacturing facility in Lund, Sweden. For more information, please visit our website at www.repligen.com.

This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, express or implied statements regarding future financial performance and position, our strategic decision to focus on the growth of our bioprocessing business, plans and objectives for future operations, our ability to successfully negotiate and consummate partnering transactions for our clinical stage assets, including RG1068, RG3039 and RG2833, plans and objectives for product development, our market share and product sales and other statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: our ability to successfully grow our bioprocessing business; our ability to successfully negotiate and consummate development and commercialization partnerships for our portfolio of therapeutic and diagnostic assets on acceptable terms, if at all; our ability to develop and commercialize products and the market acceptance of our products; reduced demand for our products that adversely impacts our future revenues, cash flows, results of operations and financial condition; our ability to obtain regulatory approvals; the success of current and future collaborative or supply relationships; our ability to compete with larger, better financed bioprocessing, pharmaceutical and biotechnology companies; our ability to successfully integrate Repligen Sweden AB; the success of our clinical trials; new approaches to the treatment of our targeted diseases; our compliance with all FDA and EMEA regulations; our ability to obtain, maintain and protect intellectual property rights for our products; the risk of litigation regarding our intellectual property rights; our limited sales capabilities; our volatile stock price; and other risks detailed in Repligen’s Annual Report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. These forward looking statements reflect management’s current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.

- more -

Repligen Appoints Jonathan I. Lieber as CFO,

September 21, 2012

Page 3 of 3

Contact:

Sondra S. Newman

Director Investor Relations

snewman@repligen.com

(781) 419-1881

# # #